Mesirow Financial Investment Management Equity Management lifted its position in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 35.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 62,671 shares of the biotechnology company’s stock after purchasing an additional 16,454 shares during the quarter. Mesirow Financial Investment Management Equity Management owned about 0.29% of Ligand Pharmaceuticals worth $8,504,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in Ligand Pharmaceuticals by 3.3% in the third quarter. Vanguard Group Inc. now owns 2,090,137 shares of the biotechnology company’s stock worth $573,721,000 after acquiring an additional 66,789 shares in the last quarter. Woodstock Corp grew its position in Ligand Pharmaceuticals by 4.6% in the fourth quarter. Woodstock Corp now owns 69,759 shares of the biotechnology company’s stock worth $9,466,000 after acquiring an additional 3,051 shares in the last quarter. Fisher Asset Management LLC grew its position in Ligand Pharmaceuticals by 55.1% in the fourth quarter. Fisher Asset Management LLC now owns 66,105 shares of the biotechnology company’s stock worth $8,970,000 after acquiring an additional 23,486 shares in the last quarter. Rehmann Capital Advisory Group grew its position in Ligand Pharmaceuticals by 26,645.0% in the third quarter. Rehmann Capital Advisory Group now owns 93,875 shares of the biotechnology company’s stock worth $342,000 after acquiring an additional 93,524 shares in the last quarter. Finally, Pacer Advisors Inc. purchased a new position in Ligand Pharmaceuticals in the third quarter worth $368,000.

NASDAQ LGND opened at $112.40 on Monday. The company has a quick ratio of 10.50, a current ratio of 10.59 and a debt-to-equity ratio of 1.09. Ligand Pharmaceuticals Inc. has a 12-month low of $98.56 and a 12-month high of $278.62. The stock has a market cap of $2.43 billion, a price-to-earnings ratio of 17.90, a price-to-earnings-growth ratio of 1.17 and a beta of 1.40.

Ligand Pharmaceuticals (NASDAQ:LGND) last posted its quarterly earnings results on Thursday, February 7th. The biotechnology company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.48. Ligand Pharmaceuticals had a net margin of 57.00% and a return on equity of 26.00%. The business had revenue of $59.59 million during the quarter, compared to analyst estimates of $52.58 million. During the same period in the prior year, the business posted $1.31 earnings per share. The company’s revenue was up 18.1% on a year-over-year basis. Sell-side analysts predict that Ligand Pharmaceuticals Inc. will post 4.88 earnings per share for the current fiscal year.

LGND has been the subject of several research reports. HC Wainwright reiterated a “buy” rating and issued a $281.00 target price on shares of Ligand Pharmaceuticals in a research report on Monday, November 5th. Roth Capital upgraded shares of Ligand Pharmaceuticals from a “neutral” rating to a “buy” rating and cut their target price for the stock from $250.00 to $195.00 in a research report on Monday, October 29th. Zacks Investment Research upgraded shares of Ligand Pharmaceuticals from a “hold” rating to a “buy” rating and set a $126.00 target price for the company in a research report on Wednesday, January 23rd. TheStreet lowered shares of Ligand Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Wednesday, January 2nd. Finally, ValuEngine upgraded shares of Ligand Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $238.00.

ILLEGAL ACTIVITY WARNING: “Ligand Pharmaceuticals Inc. (LGND) Shares Bought by Mesirow Financial Investment Management Equity Management” was reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this report can be accessed at https://www.watchlistnews.com/ligand-pharmaceuticals-inc-lgnd-shares-bought-by-mesirow-financial-investment-management-equity-management/2813119.html.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer.

Read More: Reverse Stock Split

Institutional Ownership by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.